Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trialJingxin Li, Tao Zhu, Wei Chen et al.|The Lancet Respiratory Medicine|2022Cited by 172
RNAi-Mediated Silencing of Paramyosin Expression in Trichinella spiralis Results in Impaired Viability of the ParasiteXiaoqin Chen, Xinping Zhu|PLoS ONE|2012Cited by 63
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trialRong Tang, Tao Zhu, Hui Zheng et al.|The Lancet Respiratory Medicine|2023Cited by 58
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trialLairun Jin, Fengcai Zhu, Rong Tang et al.|Emerging Microbes & Infections|2022Cited by 30
Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previouslyLairun Jin, Fengcai Zhu, Rong Tang et al.|medRxiv|2022Cited by 10